{"name":"Bigespas LTD","slug":"bigespas-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DMB-I (INN: Latrepirdine)","genericName":"DMB-I (INN: Latrepirdine)","slug":"dmb-i-inn-latrepirdine","indication":"Alzheimer's disease","status":"phase_3"}]}],"pipeline":[{"name":"DMB-I (INN: Latrepirdine)","genericName":"DMB-I (INN: Latrepirdine)","slug":"dmb-i-inn-latrepirdine","phase":"phase_3","mechanism":"Latrepirdine is a neuroprotective agent that modulates mitochondrial function and reduces neuronal excitotoxicity through multiple pathways including NMDA receptor antagonism and monoamine oxidase inhibition.","indications":["Alzheimer's disease","Mild to moderate cognitive impairment"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}